Key facts
- This page summarizes Kristen Harrington-Smith's Form 4 filing for ImmunoGen, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Nov 2022, 16:31.
Kristen Harrington-Smith - 15 Nov 2022 Form 4 Insider Report for ImmunoGen, Inc.
- Reporting relationship
- SVP & CHIEF COMMERCIAL OFFICER
- Issuer ticker
- N/A
- Reported as of
- 15 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Nov 2022, 16:31:28 UTC
- Prior SEC filing
- 13 Jun 2022
- Next SEC filing
- 24 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kristen Harrington-Smith filed Form 4 for ImmunoGen, Inc. on 18 Nov 2022.
Change
- Previous filing in this sequence was filed on 13 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 15 Nov 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 15 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Kristen Harrington-Smith is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
Footnote F2
The RSUs vest over a three-year period, with one-third of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.